On June 17, 2025, Plus Therapeutics, Inc. made adjustments to a previous securities agreement from March 4, 2025, including the cancellation of certain warrants and the return of shares amounting to 12.24 million. The changes aimed to reduce dilution and included modifications to warrant terms and registration rights.